Advertisement

Journal of Cancer Survivorship

, Volume 11, Issue 1, pp 92–101 | Cite as

Psychotropic drug dispensing in people with and without cancer in France

  • Pierre Verger
  • Sébastien CortaredonaEmail author
  • Marie Tournier
  • Dominique Rey
  • Marc-Karim Bendiane
  • Patrick Peretti-Watel
  • Hélène Verdoux
Article

Abstract

Purpose

To compare annual and monthly prevalence of psychotropic drug (PD) dispensing and the number and duration of psychotropic treatment episodes among people with and without cancer over a 2-year follow-up.

Methods

We studied the following two cohorts of adult patients affiliated with the National Health Insurance Fund (NHIF): cancer patients followed for 2 years after diagnosis and individuals without cancer matched to cancer patients. Using information about anxiolytic, hypnotic, antidepressant, and antipsychotic dispensing in community pharmacies, we applied conditional log-binomial regressions to estimate adjusted relative risks for monthly dispensing of PDs.

Results

Annual prevalence of PD dispensing—all categories included—among cancer patients was significantly higher for almost all the categories we studied than among individuals without cancer. Monthly prevalence of anxiolytic/hypnotic dispensing started to rise several months before diagnosis and peaked immediately after. Among patients with cancer and their matched controls, treatment duration exceeded 1 month for hypnotics in 40 and 35 %, respectively (p < 0.01), and 3 months for anxiolytics in 23 and 23 % (p = 0.8); it was less than 6 months for antidepressants in 76 and 75 % (p = 0.5).

Conclusions

Prevalence of psychotropic treatment was higher among cancer patients than among persons without cancer. Psychotropic treatment duration was not in line with recommendations for significant fractions of cancer patients or their controls.

Implications for cancer survivors

Training of health professionals involved in cancer supportive care should be reinforced and specific guidelines developed to help them address psychological distress of cancer survivors.

Keywords

Cancer Survivors Oncology Psychotropic drugs Health insurance reimbursement Quality of health care 

Notes

Acknowledgments

All the members of the VICAN Group, Thomas Aparicio, Emmanuel Babin, François Beck, Anne-Deborah Bouhnik, Robert Benamouzig, Cyril Bérenger, Dominique Bessette, Philippe-Jean Bousquet, Marie-Claude Cabanel-Gicquel, Marianick Cavallini-Lambert, Michèle Chantry, Claire Chauvet, Véronique Danguy, Michel Dorval, Jean-Baptiste Herbet, Laetitia Huiart, Xavier Joutard, Anne-Gaëlle Le Corroller-Soriano, Julien Mancini, Mégane Méresse, Jean-François Morere, Herman Nabi, Alain Paraponaris, Marie Préau, Christel Protière, Frédérique Retornaze, Benoit Riandey, Luis Sagaon-Teyssier, Aurélia Tison, Valérie Séror, Archana Singh-Manoux, and Catherine Thieblemont, are acknowledged. We thank Jo Ann Cahn for her help in editing the manuscript.

Compliance with ethical standards

Funding

Study design and data collection of the VICAN study were funded by the National Institute of Cancer (Contrat de recherche et développement no. 05-2011; http://www.e-cancer.fr). This study was also partly supported by research fundings from the Paca Cancéropôle (http://canceropole-paca.com) and the French National Agency for Medicines and Health Products Safety (grant number 2014S029; http://ansm.sante.fr). These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was also approved by the French Commission on Individual Data Protection and Public Liberties (Commission Nationale Informatique et Libertés; study registered under no. 911,290). Patient information was anonymized and de-identified prior to analysis.

Informed consent

Informed consent was obtained from all individual participants included in the VICAN study.

Supplementary material

11764_2016_569_MOESM1_ESM.pdf (156 kb)
ESM 1 (PDF 156 kb)
11764_2016_569_MOESM2_ESM.pdf (23 kb)
ESM 2 (PDF 22 kb)
11764_2016_569_MOESM3_ESM.pdf (119 kb)
ESM 3 (PDF 119 kb)
11764_2016_569_MOESM4_ESM.pdf (196 kb)
ESM 4 (PDF 196 kb)

References

  1. 1.
    Bosetti C, Bertuccio P, Malvezzi M, Levi F, Chatenoud L, Negri E, et al. Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Ann Oncol. 2013;24(10):2657–71. doi: 10.1093/annonc/mdt301.CrossRefPubMedGoogle Scholar
  2. 2.
    Kanavos P. The rising burden of cancer in the developing world. Ann Oncol. 2006;17(Suppl 8):viii15–23. doi: 10.1093/annonc/mdl983.PubMedGoogle Scholar
  3. 3.
    Alfano CM, Rowland JH. Recovery issues in cancer survivorship: a new challenge for supportive care. Cancer J. 2006;12(5):432–43.CrossRefPubMedGoogle Scholar
  4. 4.
    Rowland JH, Hewitt M, Ganz PA. Cancer survivorship: a new challenge in delivering quality cancer care. J Clin Oncol. 2006;24(32):5101–4. doi: 10.1200/JCO.2006.09.2700.CrossRefPubMedGoogle Scholar
  5. 5.
    Bredart A, Kop JL, Griesser AC, Fiszer C, Zaman K, Panes-Ruedin B, et al. Assessment of needs, health-related quality of life, and satisfaction with care in breast cancer patients to better target supportive care. Ann Oncol. 2013;24(8):2151–8. doi: 10.1093/annonc/mdt128.CrossRefPubMedGoogle Scholar
  6. 6.
    Jacobsen PB, Donovan KA, Trask PC, Fleishman SB, Zabora J, Baker F, et al. Screening for psychologic distress in ambulatory cancer patients. Cancer. 2005;103(7):1494–502. doi: 10.1002/cncr.20940.CrossRefPubMedGoogle Scholar
  7. 7.
    Strong V, Waters R, Hibberd C, Rush R, Cargill A, Storey D, et al. Emotional distress in cancer patients: the Edinburgh Cancer Centre symptom study. Br J Cancer. 2007;96(6):868–74. doi: 10.1038/sj.bjc.6603626.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Desplenter F, Bond C, Watson M, Burton C, Murchie P, Lee AJ, et al. Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case-control study. Br J Cancer. 2012;107(9):1644–51. doi: 10.1038/bjc.2012.364.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr. 2004;32:57–71. doi: 10.1093/jncimonographs/lgh014.CrossRefGoogle Scholar
  10. 10.
    Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160–74. doi: 10.1016/S1470-2045(11)70002-X.CrossRefPubMedGoogle Scholar
  11. 11.
    Mitchell AJ, Ferguson DW, Gill J, Paul J, Symonds P. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol. 2013;14(8):721–32. doi: 10.1016/S1470-2045(13)70244-4.CrossRefPubMedGoogle Scholar
  12. 12.
    Ng CG, Boks MP, Smeets HM, Zainal NZ, de Wit NJ. Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands. Psychooncology. 2013;22(4):762–7. doi: 10.1002/pon.3056.CrossRefPubMedGoogle Scholar
  13. 13.
    Reece JC, Chan YF, Herbert J, Gralow J, Fann JR. Course of depression, mental health service utilization and treatment preferences in women receiving chemotherapy for breast cancer. Gen Hosp Psychiatry. 2013;35(4):376–81. doi: 10.1016/j.genhosppsych.2013.03.017.CrossRefPubMedGoogle Scholar
  14. 14.
    Caruso R, Grassi L, Nanni MG, Riba M. Psychopharmacology in psycho-oncology. Curr Psychiatry Rep. 2013;15(9):393. doi: 10.1007/s11920-013-0393-0.CrossRefPubMedGoogle Scholar
  15. 15.
    Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry. 2008;30(2):112–26. doi: 10.1016/j.genhosppsych.2007.10.008.CrossRefPubMedGoogle Scholar
  16. 16.
    Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart A, Goldhirsch A. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet. 2000;356(9238):1326–7. doi: 10.1016/S0140-6736(00)02821-X.CrossRefPubMedGoogle Scholar
  17. 17.
    Thekdi SM, Trinidad A, Roth A. Psychopharmacology in cancer. Curr Psychiatry Rep. 2015;17(1):529. doi: 10.1007/s11920-014-0529-x.CrossRefPubMedGoogle Scholar
  18. 18.
    Derogatis LR, Feldstein M, Morrow G, Schmale A, Schmitt M, Gates C, et al. A survey of psychotropic drug prescriptions in an oncology population. Cancer. 1979;44(5):1919–29.CrossRefPubMedGoogle Scholar
  19. 19.
    Goldberg RJ, Mor V. A survey of psychotropic use in terminal cancer patients. Psychosomatics. 1985;26(9):745–8 . doi: 10.1016/S0033-3182(85)72803-4.51CrossRefPubMedGoogle Scholar
  20. 20.
    Jaeger H, Morrow GR, Carpenter PJ, Brescia F. A survey of psychotropic drug utilization by patients with advanced neoplastic disease. Gen Hosp Psychiatry. 1985;7(4):353–60.CrossRefPubMedGoogle Scholar
  21. 21.
    Stiefel FC, Kornblith AB, Holland JC. Changes in the prescription patterns of psychotropic drugs for cancer patients during a 10-year period. Cancer. 1990;65(4):1048–53.CrossRefPubMedGoogle Scholar
  22. 22.
    Farriols C, Ferrandez O, Planas J, Ortiz P, Mojal S, Ruiz AI. Changes in the prescription of psychotropic drugs in the palliative care of advanced cancer patients over a seven-year period. J Pain Symptom Manag. 2012;43(5):945–52. doi: 10.1016/j.jpainsymman.2011.05.010.CrossRefGoogle Scholar
  23. 23.
    de Bock GH, Musters RF, Bos HJ, Schroder CP, Mourits MJ, de Jong-van den Berg LT. Psychotropic medication during endocrine treatment for breast cancer. Support Care Cancer. 2012;20(7):1533–40. doi: 10.1007/s00520-011-1242-5.CrossRefPubMedGoogle Scholar
  24. 24.
    Sanjida S, Janda M, Kissane D, Shaw J, Pearson S-A, DiSipio T et al. A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients. Psychooncology. 2016:n/a-n/a. doi: 10.1002/pon.4048.
  25. 25.
    Brelin S, Loge JH, Skurtveit S, Johannesen TB, Aass N, Ottesen S, et al. Antidepressants to cancer patients during the last year of life—a population-based study. Psychooncology. 2013;22(3):506–14. doi: 10.1002/pon.3059.CrossRefPubMedGoogle Scholar
  26. 26.
    Khan NF, Ward AM, Watson E, Rose PW. Consulting and prescribing behaviour for anxiety and depression in long-term survivors of cancer in the UK. Eur J Cancer. 2010;46(18):3339–44. doi: 10.1016/j.ejca.2010.07.035.CrossRefPubMedGoogle Scholar
  27. 27.
    Pearson SA, Abrahamowicz M, Srasuebkul P, Buckley NA. Antidepressant therapy in cancer patients: initiation and factors associated with treatment. Pharmacoepidemiol Drug Saf. 2015;24(6):600–9. doi: 10.1002/pds.3753.CrossRefPubMedGoogle Scholar
  28. 28.
    Bouhnik AD, Bendiane MK, Cortaredona S, Sagaon Teyssier L, Rey D, Berenger C, et al. The labour market, psychosocial outcomes and health conditions in cancer survivors: protocol for a nationwide longitudinal survey 2 and 5 years after cancer diagnosis (the VICAN survey). BMJ Open. 2015;5(3):e005971. doi: 10.1136/bmjopen-2014-005971.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    National Cancer Institute. Cancer epidemiology in mainland France: incidence and mortality. National Cancer Institute. 2014. http://www.e-cancer.fr/Professionnels-de-sante/Les-chiffres-du-cancer-en-France/Epidemiologie-des-cancers. Accessed 1 Feb 2015.
  30. 30.
    Martin-Latry K, Begaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf. 2010;19(3):256–65. doi: 10.1002/pds.1912.CrossRefPubMedGoogle Scholar
  31. 31.
    Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–43. doi: 10.1016/S0140-6736(12)60240-2.CrossRefPubMedGoogle Scholar
  32. 32.
    Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150–61. doi: 10.1002/pst.433.CrossRefPubMedGoogle Scholar
  33. 33.
    WHO Collaborating Centre for Drug Statistics Methodology: about the ATC/DDD system. Norwegian Institute of Public Health. 2007. http://www.whocc.no/atc_ddd_methodology/purpose_of_the_atc_ddd_system. . Accessed 1 Feb 2015.
  34. 34.
    Bocquier A, Cortaredona S, Verdoux H, Sciortino V, Nauleau S, Verger P. Social inequalities in new antidepressant treatment: a study at the individual and neighborhood levels. Ann Epidemiol. 2013;23(3):99–105. doi: 10.1016/j.annepidem.2012.12.008.CrossRefPubMedGoogle Scholar
  35. 35.
    Etchepare F, Sanglier T, Andre M, Verdoux H, Tournier M. Antidepressant treatment patterns in younger and older adults from the general population in a real-life setting. Int J Geriatr Psychiatry. 2014;29(9):928–35. doi: 10.1002/gps.4081.CrossRefPubMedGoogle Scholar
  36. 36.
    Tournier M, Crott R, Gaudron Y, Verdoux H. Economic impact of antidepressant treatment duration in naturalistic conditions. Acta Psychiatr Scand. 2013;127(5):365–72. doi: 10.1111/acps.12035.CrossRefPubMedGoogle Scholar
  37. 37.
    Verdoux H, Cougnard A, Thiebaut A, Tournier M. Impact of duration of antidepressant treatment on the risk of occurrence of a new sequence of antidepressant treatment. Pharmacopsychiatry. 2011;44(3):96–101. doi: 10.1055/s-0031-1271686.CrossRefPubMedGoogle Scholar
  38. 38.
    Huber CA, Szucs TD, Rapold R, Reich O. Identifying patients with chronic conditions using pharmacy data in Switzerland: an updated mapping approach to the classification of medications. BMC Public Health. 2013;13:1030. doi: 10.1186/1471-2458-13-1030.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Grolleau A, Cougnard A, Begaud B, Verdoux H. Psychotropic drug use and correspondence with psychiatric diagnoses in the mental health in the general population survey. L’Encéphale. 2008;34(4):352–9. doi: 10.1016/j.encep.2007.07.011.CrossRefPubMedGoogle Scholar
  40. 40.
    Kim SW, Shin IS, Kim JM, Kim YC, Kim KS, Kim KM, et al. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci. 2008;62(1):75–83. doi: 10.1111/j.1440-1819.2007.01778.x.CrossRefPubMedGoogle Scholar
  41. 41.
    Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4:CD005454. doi: 10.1002/14651858.CD005454.pub2.Google Scholar
  42. 42.
    Smith AB, King M, Butow P, Luckett T, Grimison P, Toner GC, et al. The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. Psychooncology. 2013;22(11):2557–64. doi: 10.1002/pon.3323.CrossRefPubMedGoogle Scholar
  43. 43.
    Mazzocato C, Stiefel F, Buclin T, Berney A. Psychopharmacology in supportive care of cancer: a review for the clinician: II. Neuroleptics Support Care Cancer. 2000;8(2):89–97.CrossRefPubMedGoogle Scholar
  44. 44.
    Brocken P, Prins JB, Dekhuijzen PN, van der Heijden HF. The faster the better?—a systematic review on distress in the diagnostic phase of suspected cancer, and the influence of rapid diagnostic pathways. Psychooncology. 2012;21(1):1–10.CrossRefPubMedGoogle Scholar
  45. 45.
    Howell D, Oliver TK, Keller-Olaman S, Davidson JR, Garland S, Samuels C, et al. Sleep disturbance in adults with cancer: a systematic review of evidence for best practices in assessment and management for clinical practice. Ann Oncol. 2014;25(4):791–800. doi: 10.1093/annonc/mdt506.CrossRefPubMedGoogle Scholar
  46. 46.
    French National Authority for Health. Strategies of stopping benzodiazepine treatments: stakes and ways. French National Authority for Health. 2015. http://www.has-sante.fr/portail/jcms/c_747367/n7-focus. Accessed 1 Feb 2015.
  47. 47.
    Richards D. NHS clinical knowledge summaries. Evid Based Dent. 2009;10(4):118–9. doi: 10.1038/sj.ebd.6400690.CrossRefPubMedGoogle Scholar
  48. 48.
    Jardin M, Bocquier A, Cortaredona S, Nauleau S, Millon C, Savard-Chambard S, et al. Potentially inappropriate prescriptions for the elderly: a study of health insurance reimbursements in southeastern France. Rev Epidemiol Sante Publique. 2012;60(2):121–30. doi: 10.1016/j.respe.2011.10.004.CrossRefPubMedGoogle Scholar
  49. 49.
    Anthierens S, Pasteels I, Habraken H, Steinberg P, Declercq T, Christiaens T. Barriers to nonpharmacologic treatments for stress, anxiety, and insomnia: family physicians’ attitudes toward benzodiazepine prescribing. Can Fam Physician. 2010;56(11):e398–406.PubMedPubMedCentralGoogle Scholar
  50. 50.
    French National Authority for Health. Guide—chronic disease status 30. French National Authority for Health. 2011. http://www.has-sante.fr/portail/jcms/c_645938/fr/tumeur-maligne-affection-maligne-du-tissu-lymphatique-ou-hematopoietique. Accessed 1 Feb 2015.
  51. 51.
    Holland JC, Andersen B, Breitbart WS, Compas B, Dudley MM, Fleishman S, et al. Distress management. J Natl Compr Cancer Netw. 2010;8(4):448–85.Google Scholar
  52. 52.
    National Institute for Health and Clinical Excellence. NICE clinical guideline CG90: the treatment and management of depression in adults. National Institute for Health and Clinical Excellence. 2009. https://www.nice.org.uk/guidance/cg90. Accessed 1 Feb 2015.
  53. 53.
    National Institute for Health and Clinical Excellence. NICE clinical guideline CG91: depression in adults with chronic physical health problem: recognition and management. National Institute for Health and Clinical Excellence. 2009. https://www.nice.org.uk/guidance/cg91. Accessed 1 Feb 2015.
  54. 54.
    Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009;374(9690):609–19. doi: 10.1016/S0140-6736(09)60879-5.CrossRefPubMedGoogle Scholar
  55. 55.
    Mayo Clinic Staff. Diseases and conditions: adjustment disorders. Mayo Clinic. 2014. http://www.mayoclinic.org/diseases-conditions/adjustment-disorders/basics/tests-diagnosis/con-20031704. Accessed 20 Jul 2016.
  56. 56.
    Vaidya R, Sood R, Karlin N, Jatoi A. Benzodiazepine use in breast cancer survivors: findings from a consecutive series of 1,000 patients. Oncology. 2011;81(1):9–11. doi: 10.1159/000330814.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Linden W, MacKenzie R, Rnic K, Marshall C, Vodermaier A. Emotional adjustment over 1 year post-diagnosis in patients with cancer: understanding and predicting adjustment trajectories. Support Care Cancer. 2015;23(5):1391–9. doi: 10.1007/s00520-014-2492-9.CrossRefPubMedGoogle Scholar
  58. 58.
    Fiszer C, Dolbeault S, Sultan S, Bredart A. Prevalence, intensity, and predictors of the supportive care needs of women diagnosed with breast cancer: a systematic review. Psychooncology. 2014;23(4):361–74. doi: 10.1002/pon.3432.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.INSERM, UMR912 (SESSTIM)MarseilleFrance
  2. 2.Aix Marseille Université, UMR_S912, IRDMarseilleFrance
  3. 3.ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d’AzurMarseilleFrance
  4. 4.Université de Bordeaux, U657BordeauxFrance
  5. 5.INSERM, U657BordeauxFrance
  6. 6.Centre Hospitalier Charles PerrensBordeauxFrance

Personalised recommendations